Acquisition News: Mapmygenome Completes dnaPower Purchase
Mapmygenome has closed its acquisition of Vancouver-based dnaPower, widening its North American reach in DNA, microbiome, longevity and precision health testing.
Key takeaways
- Mapmygenome announced on Oct. 21, 2026, that it has completed its acquisition of dnaPower Inc., a Vancouver-based personal genomics company.
- The company says the deal expands its North American footprint and creates a platform spanning DNA, microbiome, longevity and precision health testing.
- This is a completed transaction, not a proposed one, so the focus now shifts from deal approval to integration.
- Separately, Greenbacker Renewable Energy Co LLC filed a definitive merger proxy (DEFM14A) with the SEC on Oct. 20.
What happened in this acquisition news
Mapmygenome said it has closed its purchase of dnaPower Inc., which it describes as a pioneer in personal genomics. The announcement was issued from Vancouver, where dnaPower is based, through PR Newswire on Oct. 21, 2026.
Mapmygenome frames the transaction as strategic. It says the combination widens its presence in North America and builds what it calls a market-leading platform across four testing categories: DNA, microbiome, longevity and precision health.
Why the deal matters for consumer genomics
Consumer and preventive-health testing is a crowded field. Companies tend to differentiate on the breadth of what they test and on where they can sell it. Acquiring a company already operating in Vancouver gives Mapmygenome a local base in Canada, a foothold it can use as it pursues the wider North American market.
The category list in the announcement is also notable. Pairing DNA testing with microbiome and longevity offerings points to a bundled approach to personalized health, rather than a single-test product. Mapmygenome’s stated aim is to build one platform across those areas.
Who is affected
dnaPower’s customers and partners now sit inside a larger organization. For Mapmygenome, the transaction adds a North American operating entity and a brand with a history in personal genomics. Competitors in the region will be watching whether the combined company pushes a broader product range into the market.
What to watch next
Several questions will determine whether the “accelerate expansion” language becomes concrete:
- Product rollout: whether Mapmygenome’s DNA, microbiome and longevity tests are made available through dnaPower’s operations in North America.
- Branding and structure: whether dnaPower continues as a distinct name or is folded into the Mapmygenome platform.
- Further expansion: whether the company announces additional markets or partnerships in the region.
Mapmygenome has not, in its announcement, laid out a timeline for these steps, so integration milestones will be the clearest signal of how the strategy develops.
Other deal paperwork this week
In a separate filing, Greenbacker Renewable Energy Co LLC submitted a definitive merger proxy statement, form DEFM14A, to the SEC on Oct. 20, 2026. A definitive merger proxy is the document used to put a proposed merger before shareholders for a vote. It is unrelated to the Mapmygenome transaction, but it is a reminder that the filing, which runs about 10 MB, is where details on terms and process for that deal are set out.
Snapshot
| Item | Detail |
|---|---|
| Buyer | Mapmygenome |
| Target | dnaPower Inc. (Vancouver) |
| Status | Completed, announced Oct. 21, 2026 |
| Stated focus | DNA, microbiome, longevity, precision health testing |
| Stated goal | Expand North American footprint |
For readers tracking deal announcements, the Mapmygenome transaction is a small but clear example of a cross-border buyer using an acquisition to enter a new region rather than building from scratch.
Prepared with AI assistance from public sources and reviewed under our editorial policy. Not investment advice.
